February 20, 2026

Survival Outcomes With or Without Bilateral Risk-Reducing Mastectomy in BRCA1/BRCA2 Pathogenic Variant Carriers

In a UK study reported in the Journal of Clinical Oncology, Gandhi et al found that whereas breast cancer incidence was reduced with bilateral risk-reducing mastectomy among women carrying BRCA1/BRCA2...

The ASCO Post

February 20, 2026

CLL/SLL: FDA Approves Combination of Acalabrutinib and Venetoclax

The ASCO Post

February 20, 2026

AI Tool Classifies Pediatric Brain Tumors via Liquid Biopsy

The ASCO Post

February 19, 2026

High Response Rates With Front-Line Pivekimab Sunirine in BPDCN

The ASCO Post

August 04, 2026

U.S. News & World Report Names Dana-Farber Brigham Cancer Center #1 Locally, #3 Nationally for 2026-2027

Dana-Farber

July 31, 2026

Lung Cancer Care in 2026: Earlier Detection, Earlier Intervention, More Individualized Treatment

Baptist Health South Florida

The Myelofibrosis Journey From Diagnosis to Long-Term Management

This new program delivers concise, expert-informed education to guide decision-making across all stages of myelofibrosis (MF) care.

Explore the Resource

Latest Headlines

August 04, 2026

U.S. News & World Report Names Dana-Farber Brigham Cancer Center #1 Locally, #3 Nationally for 2026-2027

Dana-Farber

July 31, 2026

Lung Cancer Care in 2026: Earlier Detection, Earlier Intervention, More Individualized Treatment

Baptist Health South Florida

July 24, 2026

EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma

The ASCO Post

July 24, 2026

Electronic Prior Authorization Requirements for Drugs

The ASCO Post

July 24, 2026

Neoadjuvant Inetetamab Plus Pyrotinib Evaluated in HER2-Positive Locally Advanced Breast Cancer in China

The ASCO Post

July 24, 2026

Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth

The ASCO Post

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

Conference Coverage

All Conference News View Conference Calendar

Cleveland Clinic's AI Summit

August 07, 2026

Cleveland Clinic's AI Summit: Explore the Future of AI-Driven Health Care

MDSpire News

ASCO Breakthrough 2026

July 24, 2026

Neoadjuvant Inetetamab Plus Pyrotinib Evaluated in HER2-Positive Locally Advanced Breast Cancer in China

The ASCO Post

July 24, 2026

Neoadjuvant Inetetamab Plus Pyrotinib Evaluated in HER2-Positive Locally Advanced Breast Cancer in China

The ASCO Post

July 24, 2026

Palliative Care Integrated at Diagnosis Improves QOL for Patients With Breast Cancer in India

The ASCO Post

ASCO 2026

July 24, 2026

EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma

The ASCO Post

July 24, 2026

Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy

The ASCO Post

July 24, 2026

EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma

The ASCO Post

Clinical Guidelines

July 24, 2026

ASCO Publishes First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

The ASCO Post

July 24, 2026

ASCO Publishes First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

The ASCO Post

July 23, 2026

FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC

The ASCO Post

July 23, 2026

FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC

The ASCO Post

Commentary & Perspectives

July 24, 2026

Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth

The ASCO Post

July 24, 2026

The Fear of Having Cancer Never Goes Away

The ASCO Post

July 24, 2026

The Fear of Having Cancer Never Goes Away

The ASCO Post

July 24, 2026

Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth

The ASCO Post

FDA & Government News

July 14, 2026

Gedatolisib Combinations Approved by FDA for HR-Positive/HER2-Negative Breast Cancer

The ASCO Post

July 14, 2026

FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion–Positive Solid Tumors

The ASCO Post

July 10, 2026

FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph—Each With Enfortumab Vedotin-ejfv—for Muscle-Invasive Bladder Cancer

The ASCO Post

July 10, 2026

FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph—Each With Enfortumab Vedotin-ejfv—for Muscle-Invasive Bladder Cancer

The ASCO Post

Business Management

May 26, 2026

First Virtual Cancer Clinic to Receive ASCO Certified Status

The ASCO Post

May 26, 2026

First Virtual Cancer Clinic to Receive ASCO Certified Status

The ASCO Post

January 29, 2025

Clinical Posters From JADPRO Live 2024

Jadpro

January 29, 2025

Clinical Posters From JADPRO Live 2024

Jadpro

Conexiant's News Site Is Now MDSpire News.

Trending Now

Strategy for Managing Immunotherapy-Induced Parkinsonism in Patients With Multiple Myeloma

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dentistry

ADA News

CDE World

New Dentist News

AACE Endocrinology AI

GI & Hepatology News

The ASCO Post

JADPRO

JNCCN

JNCCN 360

ASCO AI in Oncology

Glaucoma Physician

Ophthalmology Management

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

The Pathologist

The Medicine Maker

The Analytical Scientist

High Response Rates With Front-Line Pivekimab Sunirine in BPDCN

U.S. News & World Report Names Dana-Farber Brigham Cancer Center #1 Locally, #3 Nationally for 2026-2027

Lung Cancer Care in 2026: Earlier Detection, Earlier Intervention, More Individualized Treatment

Latest Headlines

Daily News

Recommendations

Trending Now

1

Strategy for Managing Immunotherapy-Induced Parkinsonism in Patients With Multiple Myeloma

Featured Videos

Conference Coverage

Cleveland Clinic's AI Summit

ASCO Breakthrough 2026

ASCO 2026

Clinical Guidelines

Commentary & Perspectives

FDA & Government News

Business Management